Same Meds, New Patents: What Do Activists Need to Know About Long-Acting Technologies
Webinars • 2021On November 4, 2021, Treatment Action Group and the International Treatment Preparedness Coalition presented this webinar outlining the main findings of the upcoming report "Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis on Patenting Trends."
The Challenge of Diagnosing HIV Infection in LA PrEP Users
TAGline • 2021By Richard Jefferys Impressive results from two efficacy trials of a long-acting form of the integrase inhibitor cabotegravir (CAB LA) have boosted prospects for long-acting HIV pre-exposure prophylaxis (PrEP).1,2 In both cases, CAB LA proved superior to oral Truvada PrEP (see table). Analyses of the trial data have also revealed a wrinkle associated with the…
PrEPared? Long-Acting PrEP Access in Communities Marginalized by the U.S. Healthcare System
TAGline • 2021By Abraham Johnson The announcement that HIV Prevention Trials Network (HPTN) had two successful studies on long-acting technologies (LAT) to prevent HIV — HPTN 083 and 084 — came with much excitement. Populations most impacted by HIV could possibly have an even greater opportunity to prevent HIV. LATs provide for potentially easier adherence, fewer side…
Terraforming the Policy Landscape to Enable Access to Long-Acting Technologies
TAGline • 2021By Annette Gaudino and Suraj Madoori Let’s Define Terraforming Terraforming — or “earth-shaping” — the transformation of an alien planet into one where humans can live, is probably most familiar to science-fiction fans and Minecraft players. Terraforming is more intensive than landscaping, the term used to describe the need to understand local politics to win…
Delivering on the Promise of Long-Acting Technologies
TAGline • 2021By Susan Swindells* and Mark Harrington This issue of TAGline explores the exciting opportunities and challenges that come with the development of long-acting formulations for the prevention and treatment of infectious diseases. For many years to date, patients and providers have welcomed long-acting medications for other conditions such as schizophrenia, osteoporosis, and contraception. These delivery…
Substantial Public Investments in GeneXpert Underscore Need for Affordable Pricing
Statement / Press • 2021TAG’s comprehensive analysis found that the public invested at least $252 million USD in the research and development of GeneXpert diagnostic technology, which stands in stark contrast to the lack of affordable pricing and favorable service and maintenance terms from the diagnostics company Cepheid.
Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs
Statement / Press • 2021The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.
Treatment Action Group Mourns and Resists Violence towards Black Communities; Demands Action and Accountability across Government and Systems
Statement / Press • 2020Treatment Action Group (TAG) joins partners, activists, and communities around the U.S. and the world in decrying violence against Black people and those who stand in solidarity with them.
Efficacy News from Second COVID-19 Vaccine Trial Underscores Need for Transparency and Cooperation Between Outgoing and Incoming US Administrations
Statement / Press • 2020AVAC and Treatment Action Group (TAG) welcome today’s announcement that preliminary data from the efficacy trial of Moderna’s mRNA COVID-19 vaccine indicate high-level of protection against COVID-19.
A Landscape Analysis of HIV Cure-Related Clinical Research in 2019
Publication • 2020In 2018, the Bill & Melinda Gates Foundation contracted TAG to undertake a survey of investigators conducting studies included in our “Research Toward a Cure” clinical trials listing. TAG conducted this second survey in the fall of 2019 to track any changes over time and provide updated information on status of the field.